<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940617-1-00054</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4702 -->  <!-- PJG ITAG l=21 g=1 f=1 --> (38) Letter from W. E. Gilbertson, FDA,  <!-- PJG 0012 frnewline --> to M. K. Bruch, Dexide, Inc., coded LET79,  <!-- PJG 0012 frnewline --> Docket No. 75N&hyph;0183, Dockets Management  <!-- PJG 0012 frnewline --> Branch.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (39) Memorandum of meeting between  <!-- PJG 0012 frnewline --> representatives of Dexide, Inc., Ferro Corp.,  <!-- PJG 0012 frnewline --> and FDA, coded MM11, Docket No. 75N&hyph;0183,  <!-- PJG 0012 frnewline --> Dockets Management Branch.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (40) Letter from W. E. Gilbertson, FDA,  <!-- PJG 0012 frnewline --> to M. K. Bruch, Dexide, Inc., coded LET89,  <!-- PJG 0012 frnewline --> Docket No. 75N&hyph;0183, Dockets Management  <!-- PJG 0012 frnewline --> Branch.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (41) Comment No. C165, Docket No.  <!-- PJG 0012 frnewline --> 75N&hyph;0183, Dockets Management Branch.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (42) Comment No. SUP51, Docket No.  <!-- PJG 0012 frnewline --> 75N&hyph;0183, Dockets Management Branch.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (43) Letter from W. E. Gilbertson,  <!-- PJG 0012 frnewline --> FDA, to M. K. Bruch, Dexide, Inc., coded  <!-- PJG 0012 frnewline --> LET93, Docket No. 75N&hyph;0183, Dockets  <!-- PJG 0012 frnewline --> Management Branch.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (44) Memorandum of meeting between  <!-- PJG 0012 frnewline --> representatives of Dexide, Inc., Ferro Corp.,  <!-- PJG 0012 frnewline --> and FDA, coded MM15, Docket No. 75N&hyph;0183,  <!-- PJG 0012 frnewline --> Dockets Management Branch.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (45) Comment No. C172, Docket No. 75N&hyph; <!-- PJG 0012 frnewline --> 0183, Dockets Management Branch.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (46) Letter from W. E. Gilbertson, FDA,  <!-- PJG 0012 frnewline --> to G. R. Kramzar, NIPA Laboratories, Inc.,  <!-- PJG 0012 frnewline --> coded LET97, Docket No. 75N&hyph;0183, Dockets  <!-- PJG 0012 frnewline --> Management Branch.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (47) Letter from W. E. Gilbertson, FDA  <!-- PJG 0012 frnewline --> to G. R. Kramzar, NIPA Laboratories, Inc., coded  <!-- PJG 0012 frnewline --> C174, Docket No. 75N&hyph;0183, Dockets Management  <!-- PJG 0012 frnewline --> Branch.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (48) Comment No. C173, Docket No. 75N-  <!-- PJG 0012 frnewline --> 0183, Dockets Management Branch.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (49) Comment No. LET65, vol. 4, 5, and  <!-- PJG 0012 frnewline --> 6, Docket No. 75N&hyph;0183, Dockets Management  <!-- PJG 0012 frnewline --> Branch.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (50) McCracken, A., ``Effectiveness of  <!-- PJG 0012 frnewline --> Ultradex Scrub Sponge Determined in a  <!-- PJG 0012 frnewline --> Clinical Setting,'' unpublished study, coded  <!-- PJG 0012 frnewline --> LET65, vol. 6, Docket No. 75N&hyph;0183, Dockets  <!-- PJG 0012 frnewline --> Management Branch.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (51) Letter from W. E. Gilbertson, FDA,  <!-- PJG 0012 frnewline --> to M. K. Bruch, Dexide, Inc., coded LET87,  <!-- PJG 0012 frnewline --> Docket No. 75N&hyph;0183, Dockets Management  <!-- PJG 0012 frnewline --> Branch.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            